Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

This randomised, double-blind, placebo-controlled study was designed to evaluate the ability of the orally administered matrix metalloproteinase inhibitor, marimastat, to prolong survival in patients with non-resectable gastric and gastro-oesophageal adenocarcinoma. Three hundred and sixty-nine pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Bramhall, S R, Hallissey, M T, Whiting, J, Scholefield, J, Tierney, G, Stuart, R C, Hawkins, R E, McCulloch, P, Maughan, T, Brown, P D, Baillet, M, Fielding, J W L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375430/
https://www.ncbi.nlm.nih.gov/pubmed/12085177
http://dx.doi.org/10.1038/sj.bjc.6600310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375430/
https://www.ncbi.nlm.nih.gov/pubmed/12085177
http://dx.doi.org/10.1038/sj.bjc.6600310

Ejemplares similares